As of January, 31, 2019 PDI is no longer a Publicis Health/Publicis Groupe company. Look for all our new branding soon!

Pharmaceutical Sales Strategies for Hematology Care

Hematology practices are undergoing a transition, as formerly independent clinicians associate with larger organizations to remain profitable.

Independent hematology practices are becoming financially unviable because of the high percentage of non-reimbursable time and the increased administrative requirements inherent in the practice of hematology. The economic stress hematology practices are exposed to is driven by the high percentage of time hematologists spend on non-reimbursable patient care issues and the increasing requirements for documentation and obtaining payer approval for treatment. Even though hematology was predominantly practiced in small community based practices in the past, the changing healthcare environment has driven an increasing number of hematology practices to associate with larger practices or hospitals. Nevertheless, hematologic drug development is advancing rapidly. Most emerging hematology drugs are immunotherapies for hematologic malignancies, but there is also a pipeline of new medications for hemophilia, sickle cell anemia, and other hematologic illnesses.

Maintaining continuity of care for patients is the key challenge in hematology today, and PDI can help you meet it.

Successful pharmaceutical sales strategies must be aimed at aiding hematologists in providing a stable care environment for their patients in a time of transition. Our field-based and inside medical sales representatives can educate hematologists on newly introduced pharmacological treatments, assist with decreasing their administrative burdens, and assist with securing payer approval for treatment. Our healthcare contact center can act as a further resource for provider education. Scientific dialogue with key opinion leaders may be needed to support emerging hematologic treatments. Our medical science liaisons (MSLs) are ready to engage clinicians in such high science conversations as required. Finally, our clinical health educators (CHEs) can provide the required patient education for rare hematologic conditions.

During this time of structural change, continuity of care and the integrity of the doctor-patient relationship are key concerns. Hematologists will benefit from:

  • Education on newly introduced medications
  • Assistance with patient education for rare hematologic diseases such as sickle cell anemia and myelodysplastic syndrome
  • Assistance with treatment authorizations to give patients access to needed medications and to decrease administrative workload
  • Maintaining formulary access to medications for existing patients as practice organization changes

Learn how we can assist you and your customers provide stable and state-of-the-art hematology care

Contact Us Now